Modus Therapeutics rakes in funding
Stockholm-based Modus Therapeutics, which focuses on treating patients with sickle cell disease, has raised SEK 140 million (about $15.6 million) in financing. The investor was HealthCap.
13 July 2018•1 min read
Stockholm-based Modus Therapeutics, which focuses on treating patients with sickle cell disease, has raised SEK 140 million (about $15.6 million) in financing. The investor was HealthCap.
